Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
02 sept. 2020 16h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
07 août 2020 06h30 HE
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Reports First Quarter 2020 Financial Results
06 mai 2020 06h30 HE
|
Jounce Therapeutics, Inc.
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – –...
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
06 févr. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
07 nov. 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash...
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
05 nov. 2019 08h05 HE
|
Jounce Therapeutics, Inc.
- Recommended Phase 2 dose determined for future JTX-4014 trials - - Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial - CAMBRIDGE,...
Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019
31 oct. 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
01 oct. 2019 18h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07 août 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
31 juil. 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...